Myostatin Inhibitor Apitegromab Preserves Lean Mass During Tirzepatide-Induced Weight Loss in Phase 2 Trial
Myostatin Inhibitor Apitegromab Preserves Lean Mass During Tirzepatide-Induced Weight Loss in Phase 2 Trial Dual incretin mimetics like tirzepatide show considerable effectiveness in reducing body weight in adults with obesity. However, clinical evidence shows that lean body mass makes up 25 to 40 percent of the total weight loss. This loss has significant functional and metabolic impacts on patients.
Lean mass supports physical strength, increases resting caloric burn, and lowers the risk of type 2 diabetes. A phase 2 randomized controlled trial provides early evidence that selective myostatin inhibition may help prevent this loss. Researchers enrolled 102 adults with overweight or obesity in the 24-week EMBRAZE study.
Participants were randomly assigned to receive tirzepatide plus apitegromab or tirzepatide plus placebo. Apitegromab is an investigational monoclonal antibody that specifically blocks a key inhibitor of muscle growth. At week 24, total body weight loss was similar in both treatment groups. Apitegromab did not reduce the primary weight loss effect of tirzepatide. However, participants receiving apitegromab maintained significantly more lean mass than those who got the placebo.
Specifically, the apitegromab group had 54.9 percent greater lean mass retention compared to placebo. The profile of adverse events was largely similar between the two study groups. Most adverse events were mild, affecting 76 percent of the apitegromab group and 71 percent of the placebo group. Serious adverse events were balanced, occurring in only one participant per treatment group. Still, the small size, short duration, and mostly female population in the trial limit how broadly these findings can be applied.
External commentators have called for careful interpretation of these early trial results. Experts recognize the positive indication but stress that larger and longer trials need to be done. Moreover, researchers should find out if preserving lean mass leads to measurable health improvements. Effective myostatin inhibitors could eventually improve the functional benefits linked to dual incretin therapies.
Until more evidence is available, clinicians who prescribe incretin-based therapies should promote structured physical activity. Exercise is the most reliable method for maintaining muscle mass during weight loss. Given this, the EMBRAZE results present apitegromab as a candidate for further study. Future research will assess this compound as an addition to weight loss medications.
